nach oben

Arthritis Research & Therapy

Erschienen in:

01.03.2005 | Commentary

Role of regulatory T cells in experimental arthritis and implications for clinical use

verfasst von: Marco Londei

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

CD4⁺CD25⁺ T regulatory cells are avidly studied because they modulate immune responses. Their possible role in autoimmunity and more specifically in rheumatoid arthritis (RA) has been highlighted by a string of reports, one of which is in the last issue of Arthritis Research & Therapy. There are, however, key questions that have not yet been addressed before their use can be considered as a real therapeutic option. The first is the actual, in a clinical setting, efficacy of Treg to treat active chronic autoimmune diseases such as RA. The second is how we can practically deliver their therapeutic activity in patients. Once these points have been addressed we will have a new and potentially very effective 'magic bullet' for the treatment of chronic autoimmune diseases.

Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, Hamann A, Radbruch A, Bräuer R: The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4⁺CD25⁺ T cells. Arthritis Res Ther. 2005, 7: R291-R301. 10.1186/ar1484.PubMedCentralCrossRefPubMed

Baecher-Allan C, Hafler DA: Suppressor T cells in human diseases. J Exp Med. 2004, 200: 273-276. 10.1084/jem.20040812.PubMedCentralCrossRefPubMed

Fehervari Z, Sakaguchi S: CD4⁺ Tregs and immune control. J Clin Invest. 2004, 114: 1209-1217. 10.1172/JCI200423395.PubMedCentralCrossRefPubMed

Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, et al: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001, 27: 18-20. 10.1038/83707.CrossRefPubMed

Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003, 299: 1057-1061. 10.1126/science.1079490.CrossRefPubMed

Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, de Vries RR, Toes RE: CD25⁺ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003, 48: 1452-1460. 10.1002/art.11063.CrossRefPubMed

Chu CQ, Londei M: Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J Immunol. 1996, 157: 2685-2689.PubMed

Bardos T, Czipri M, Vermes C, Finnegan A, Mikecz K, Zhang J: CD4⁺CD25⁺ immunoregulatory T cells may not be involved in controlling autoimmune arthritis. Arthritis Res Ther. 2003, 5: R106-R113. 10.1186/ar624.PubMedCentralCrossRefPubMed

Mottet C, Uhlig HH, Powrie F: Cutting edge: cure of colitis by CD4⁺CD25⁺ regulatory T cells. J Immunol. 2003, 170: 3939-3943.CrossRefPubMed

10.

Liu H, Hu B, Xu D, Liew FY: CD4⁺CD25⁺ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol. 2003, 171: 5012-5017.CrossRefPubMed

11.

Green EA, Choi Y, Flavell RA: Pancreatic lymph node-derived CD4⁺CD25⁺ Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity. 2002, 16: 183-191. 10.1016/S1074-7613(02)00279-0.CrossRefPubMed

12.

Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA: In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004, 199: 1455-1465. 10.1084/jem.20040139.PubMedCentralCrossRefPubMed

13.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10: 942-949. 10.1038/nm1093.CrossRefPubMed

14.

Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C: Isolation and functional characterization of regulatory CD25brightCD4⁺ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003, 33: 215-223. 10.1002/immu.200390024.CrossRefPubMed

15.

Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V: CD25^brightCD4⁺ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004, 6: R335-R346. 10.1186/ar1192.PubMedCentralCrossRefPubMed

16.

de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, de Jager W, Pugayung G, Giannoni F, Rijkers G, et al: CD4⁺CD25^bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol. 2004, 172: 6435-6443.CrossRefPubMed

17.

van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS: CD4⁺CD25⁺ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004, 50: 2775-2785. 10.1002/art.20499.CrossRefPubMed

18.

Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004, 200: 277-285. 10.1084/jem.20040165.PubMedCentralCrossRefPubMed

19.

Buch MH, Marzo-Ortega H, Bingham SJ, Emery P: Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Rheumatology (Oxford). 2004, 43: 243-244.CrossRef

20.

Bluestone JA, Tang Q: Therapeutic vaccination using CD4⁺CD25⁺ antigen-specific regulatory T cells. Proc Natl Acad Sci USA. 2004, 101 (Suppl 2): 14622-14626. 10.1073/pnas.0405234101.PubMedCentralCrossRefPubMed

21.

Mekala DJ, Geiger TL: Immunotherapy of autoimmune encephalomyelitis with redirected CD4⁺CD25⁺ T lymphocytes. Blood. 2005, 105: 2090-2092. 10.1182/blood-2004-09-3579.CrossRefPubMed

22.

Jaeckel E, von Boehmer H, Manns MP: Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes. 2005, 54: 306-310.CrossRefPubMed

23.

van Bilsen JH, van Dongen H, Lard LR, van der Voort EI, Elferink DG, Bakker AM, Miltenburg AM, Huizinga TW, de Vries RR, Toes RE: Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proc Natl Acad Sci USA. 2004, 101: 17180-17185. 10.1073/pnas.0407704101.PubMedCentralCrossRefPubMed

24.

Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, Amox D, Roord S, de Kleer I, Bonnin D, et al: Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA. 2004, 101: 4228-4233. 10.1073/pnas.0400061101.PubMedCentralCrossRefPubMed

Titel: Role of regulatory T cells in experimental arthritis and implications for clinical use
verfasst von: Marco Londei
Publikationsdatum: 01.03.2005
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 3/2005
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1745

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function

The mechanism of low-concentration sodium nitroprusside-mediated protection of chondrocyte death

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis

Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia